"Potassium gluconate"

Short-Term RCT of Increased Dietary Potassium from Potato or Potassium Gluconate: Effect on Blood Pressure, Microcirculation, and Potassium and Sodium Retention in Pre-Hypertensive-to-Hypertensive Adults. Increased potassium intake has been linked to improvements in cardiovascular and other health outcomes. We assessed increasing potassium intake through food or supplements as part of a controlled diet on blood pressure (BP), microcirculation (endothelial function), and potassium and sodium retention in thirty pre-hypertensive-to-hypertensive men and women. Participants were randomly assigned to a sequence of four 17 day dietary potassium treatments: a basal diet (control) of 60 mmol/d and three phases of 85 mmol/d added as potatoes, French fries, or a potassium gluconate supplement

Short-Term Supplemental Dietary Potassium from Potato and Potassium Gluconate: Effect on Calcium Retention and Urinary pH in Pre-Hypertensive-to-Hypertensive Adults. Potassium supplementation has been associated with reduced urinary calcium (Ca) excretion and increased Ca balance. Dietary interventions assessing the impact of potassium on bone are lacking. In this secondary analysis of a study

Bioavailability of potassium from potatoes and potassium gluconate: a randomized dose response trial. The bioavailability of potassium should be considered in setting requirements, but to our knowledge, the bioavailability from individual foods has not been determined. Potatoes provide 19-20% of potassium in the American diet. We compared the bioavailability and dose response of potassium from nonfried white potatoes with skin [targeted at 20, 40, and 60 milliequivalents (mEq) K] and French fries (40 mEq K) with potassium gluconate at the same doses when added to a basal diet that contained ∼60 mEq K. Thirty-five healthy, normotensive men and women with a mean ± SD age of 29.7 ± 11.2 y and body mass index (in kg/m(2)) of 24.3 ± 4.4 were enrolled in a single-blind, crossover, randomized

in increased blood perfusion to exercising skeletal muscle and therefore in ATP release from RBCs. We therefore tested the role of Panx1 in ATP release from RBCs ex vivo in RBC suspensions. We found that stimulation with hypotonic potassium gluconate buffer resulted in a significant increase in ATP in the supernatant, but this was highly correlated with RBC lysis. Next, we treated RBCs with a stable cAMP

-blind randomized crossover study.Study population: Adult outpatients (age ≥ 18 years) with CKD stage G3b or G4 using renin-angiotensin-aldosterone system inhibitors (RAAS-I).Intervention: Capsules with 40 mmol potassium chloride, potassium bicarbonate, potassium gluconate, sodium bicarbonate, sodium chloride or placebo (3 x 3 capsules per day).Main study parameters/endpoints: Difference in plasma

at increments of 10 meq. 10 meq KCL=750 mg and these are large pills. We carefully monitor potassium levels in the blood in any patient receiving potassium pills. Potassium gluconate by weight is mostly gluconate. When you say 99 mg you are referring to the mg of potassium, usually in a 595 mg K gluconate. this would provide 99/39 (molecular weight of potassium) or roughtly 2.5 meq. It would

Muscle potassium content and potassium gluconate supplementation in normokalemic cats with naturally occurring chronic renal failure. Muscle potassium content and supplementation with potassium gluconate were evaluated in normokalemic cats with chronic renal failure (CRF). Affected cats received standard medical therapy for renal failure and either placebo (sodium gluconate) or potassium significantly lower muscle potassium content than did those from normal control cats. Over the 6-month period of supplementation, muscle potassium content increased both in cats with CRF that received potassium gluconate and in those that received placebo (sodium gluconate). Serum potassium concentration and fractional excretion of potassium remained relatively unchanged in both groups of cats throughout

of the plot when the cell was held at -80 mV and stepped to various command potentials. When determined from a holding potential of -40 mV the plot was no longer biphasic. 2. In cell-attached patch experiments extracellular isotonic potassium gluconate was used to zero the cell membrane potential. When the patch electrode solution contained monovalent cations (150 mM-Li+ in most experiments) and no Ca2

METABOLISM OF d-RIBOSE-1-C14 AND C14-LABELED d-GLUCONATE IN AN ENZYME SYSTEM OF THE GENUS PROPIONIBACTERIUM Stjernholm, Rune L. (Western Reserve University, Cleveland, Ohio) and Frank Flanders. Metabolism of d-ribose-1-C(14) and C(14)-labeled d-gluconate in an enzyme system of the genus Propionibacterium. J. Bacteriol. 84:563-568. 1962.-Ribose-1-C(14) and potassium gluconate labeled in different

the absence of K+ conductances comparable to those for Na+ in the apical membranes of taste cells. This was supported by the strong anion dependence of K salt responses. At zero current clamp, the potassium gluconate (KGlu) threshold was > 250 mM, and onset kinetics were slow (12 s to reach half-maximal response). Faster onset kinetics and larger responses to KGlu occurred at negative voltage clamp (-50 mV

depolarization that was blocked by pre-incubation with the subtype 2 bombesin (BB2) receptor antagonist [D-Phe6, Des-Met14]bombesin-(6-14)ethyl amide. 2. The inward current elicited by NMB or GRP was unaffected by K+ channel blockade with external Ba2+ or by replacement of potassium gluconate in the electrode solution with caesium acetate. 3. Replacement of external NaCl with Tris-HCl significantly reduced

Bioavailability of Potassium From Potatoes and Potassium Gluconate Bioavailability of Potassium From Potatoes and Potassium Gluconate - Full Text View - ClinicalTrials.gov Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort. Hide glossary GlossaryStudy record managers: refer to the Data Element Definitions if submitting registration or results information ).Please remove one or more studies before adding more. Bioavailability of Potassium From Potatoes and Potassium Gluconate (Potato) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier

, double-blind trial of the effect of a single dose of potassium on ADHD symptoms as measured by changes in measures of symptoms of ADHD correlated with the results of their Lidocaine Effectiveness Test.Condition or disease Intervention/treatment Phase ADHD Drug: Potassium Gluconate Oral Capsule Drug: Placebo oral capsule potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is effective Drug: Potassium Gluconate Oral CapsuleEach subject will receive a dose of ~8 mg/kg of potassium. We will be giving a maximum of 14 mEq in a single dose. Placebo Comparator: Lidocaine-effective ADHD: PlaceboSingle-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is effective

Retention of Potassium From Potatoes and Potassium Gluconate, and the Effect on Blood Pressure. Retention of Potassium From Potatoes and Potassium Gluconate, and the Effect on Blood Pressure. - Full Text View - ClinicalTrials.gov Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort. Hide glossary GlossaryStudy record managers: refer to the Data Element reached the maximum number of saved studies (100).Please remove one or more studies before adding more. Retention of Potassium From Potatoes and Potassium Gluconate, and the Effect on Blood Pressure. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our